Prognostic role of MRP1 in localized high-risk soft tissue sarcoma (STS): Translational research associated to randomized phase III trial (ISG-STS).

被引：0
|
作者：
Martin Broto, Javier
Silva Moura, David
Ramos, Rafael
Braglia, Luca
Collini, Paola
Renne, Salvatore L.
Romagosa, Cleofe
Coindre, Jean Michel
Velasco, Valerie
Merlo, Domenico F.
Palmerini, Emanuela
Stacchiotti, Silvia
Quagliuolo, Vittorio
Lopez-Pousa, Antonio
Grignani, Giovanni
Blay, Jean-Yves
Brunello, Antonella
Picci, Piero
Casali, Paolo Giovanni
Gronchi, Alessandro
机构：
[1] Univ Seville, Virgen del Rocio Univ Hosp, Inst Biomed Res IBIS, CSIC, Seville, Spain
[2] Univ Seville, Inst Biomed Seville, Grp Adv Therapies & Biomarkers Sarcomas, Ibis,Hosp Univ Virgen Del Rocio,CSIC, Seville, Spain
[3] Hosp Univ Son Espases, Palma de Mallorca, Spain
[4] IRCCS Azienda Osped Univ San Martino, IST Ist Nazl Ric Canc, Clin Trial Ctr, Genoa, Italy
[5] IRCCS Azienda Osped Univ San Martino, IST Ist Nazl Ric Canc, Dept Epidemiol, Genoa, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Dept Diagnost Pathol & Lab Med, Soft Tissue & Bone Pathol Histopathol & Pediat Pa, Milan, Italy
[7] Humanitas Res Hosp, Anat Pathol Unit, Milan, Italy
[8] H Vall dHebron, Barcelona, Spain
[9] Inst Bergonie, Bordeaux, France
[10] Inst Bergonie, Dept Pathol, Bordeaux, France
[11] IRCCS Ist Ortoped Rizzoli, Bologna, Italy
[12] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[13] Ist Clin Humanitas, Milan, Italy
[14] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[15] FPO IRCCS, Candiolo Canc Inst, Div Med Oncol, Candiolo, TO, Italy
[16] UNICANCER, Ctr Leon Berard, Lyon, France
[17] Ist Oncol Veneto IRCCS, Med Oncol Unit 1, Clin & Expt Oncol Dept, Padua, Italy
[18] Italian Sarcoma Grp, Bologna, Italy
[19] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Adult Mesenchymal & Rare Tumor Unit, Milan, Italy
[20] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Sarcoma Serv, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
欧洲研究理事会;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1001
引用
收藏
页数：2
相关论文
共 50 条
  • [41] First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults.
    Lindner, LH
    Schlemmer, M
    Hohenberger, P
    Wust, P
    Abdel-Rahman, S
    Schmidt, M
    Judson, I
    Blay, JY
    Verweij, J
    Issels, RD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 821S - 821S
  • [42] PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients
    Van der Graaf, Winette T. A.
    Blay, Jean-Yves
    Chawla, Sant P.
    Kim, Dong-Wan
    Binh Bui Nguyen
    Casali, Paolo Giovanni
    Schoffski, Patrick
    Aglietta, Massimo
    Staddon, Arthur P.
    Beppu, Yasuo
    Le Cesne, Axel
    Gelderblom, Hans
    Judson, Ian Robert
    Araki, Nobuhito
    Ouali, Monia
    Marreaud, Sandrine
    Hodge, Rachel
    Dewji, Mohamedraza
    Dei Tos, Angelo Paolo
    Hohenberger, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Early response to neoadjuvant chemotherapy (NAC) in combination with regional hyperthermia (RHT) to predict long-term survival for adult-type high-risk soft tissue sarcoma (HR-STS): Results of the EORTC-ESHO intergroup phase III study.
    Issels, Rolf D.
    Kampmann, Eric
    Lindner, Lars
    Dieterle, Nelli
    Mansmann, Ulrich Robert
    Verweij, Jaap
    Kirchner, Thomas
    Wendtner, Clemens Martin
    Wessalowski, Ruediger
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Effectiveness of Regional Hyperthermia With Chemotherapy for High-Risk Retroperitoneal and Abdominal Soft-Tissue Sarcoma After Complete Surgical Resection A Subgroup Analysis of a Randomized Phase-III Multicenter Study
    Angele, Martin K.
    Albertsmeier, Markus
    Prix, Niclas J.
    Hohenberger, Peter
    Abdel-Rahman, Sultan
    Dieterle, Nelli
    Schmidt, Michael
    Mansmann, Ulrich
    Bruns, Christiane J.
    Issels, Rolf D.
    Jauch, Karl-Walter
    Lindner, Lars H.
    ANNALS OF SURGERY, 2014, 260 (05) : 749 - 756
  • [45] Risk assessment of early progression among 213 pts with high-risk soft tissue sarcomas (HR-STS) treated with neoadjuvant chemotherapy ± regional hyperthermia:: EORTC 62961/ESHO-RHT 95 intergroup phase III study.
    Lindger, LH
    Schlemmer, M
    Hohenberger, P
    Wust, P
    Schmidt, M
    Verweij, J
    Judson, I
    Jauch, KW
    Hiddemann, W
    Issels, RD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 821S - 821S
  • [46] Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma The EORTC 62961-ESHO 95 Randomized Clinical Trial
    Issels, Rolf D.
    Lindner, Lars H.
    Verweij, Jaap
    Wessalowski, Rudiger
    Reichardt, Peter
    Wust, Peter
    Ghadjar, Pirus
    Hohenberger, Peter
    Angele, Martin
    Salat, Christoph
    Vujaskovic, Zeljko
    Daugaard, Soeren
    Mella, Olav
    Mansmann, Ulrich
    Durr, Hans Roland
    Knosel, Thomas
    Abdel-Rahman, Sultan
    Schmidt, Michael
    Hiddemann, Wolfgang
    Jauch, Karl-Walter
    Belka, Claus
    Gronchi, Alessandro
    JAMA ONCOLOGY, 2018, 4 (04) : 483 - 492
  • [47] Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial
    Issels, Rolf D.
    Noessner, Elfriede
    Lindner, Lars H.
    Schmidt, Michael
    Albertsmeier, Markus
    Blay, Jean-Yves
    Stutz, Emanuel
    Xu, Yujun
    Buecklein, Veit
    Altendorf-Hofmann, Annelore
    Abdel-Rahman, Sultan
    Mansmann, Ulrich
    von Bergwelt-Baildon, Michael
    Knoesel, Thomas
    EUROPEAN JOURNAL OF CANCER, 2021, 158 : 123 - 132
  • [48] Impact of tumor infiltrating lymphocytes (TILs) on local progression-free (LPFS) and disease-free (DFS) survival in localized high-risk soft tissue sarcoma (HR-STS) after neo-adjuvant chemotherapy (NAC) with regional hyperthermia (RHT)
    Issels, R. D.
    Kampmann, E.
    Buecklein, V.
    Noessner, E.
    Lindner, L. H.
    Schmidt, M.
    Mansmann, U.
    Hiddemann, W.
    Subklewe, M.
    Knoesel, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 3 - 3
  • [49] PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072).
    Van der Graaf, W. T.
    Blay, J.
    Chawla, S. P.
    Kim, D.
    Nguyen, B. Bui
    Casali, P. G.
    Schoeffski, P.
    Aglietta, M.
    Staddon, A. P.
    Beppu, Y.
    Le Cesne, A.
    Gelderblom, H.
    Judson, I. R.
    Araki, N.
    Ouali, M.
    Marreaud, S.
    Hodge, R.
    Dewji, M.
    Dei Tos, A. P.
    Hohenberger, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072)
    Van Der Graaf, W. T.
    Blay, J.
    Chawla, S. P.
    Kim, D.
    Nguyen, B. Bui
    Casali, P. G.
    Schoeffski, P.
    Aglietta, M.
    Staddon, A. P.
    Beppu, Y.
    Le Cesne, A.
    Gelderblom, H.
    Judson, I. R.
    Araki, N.
    Ouali, M.
    Marreaud, S.
    Hodge, R.
    Dewji, M.
    Dei Tos, A. P.
    Hohenberger, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
12345